What Does an ESR1 Mutation Mean?

ESR1 is the gene for the estrogen receptor alpha, the protein that hormone receptor-positive breast cancer uses to grow. Most ESR1 mutations are not present when the cancer is first found. They emerge later, under the pressure of treatment.

The mechanism is worth understanding, because it explains why the finding changes drugs.

Aromatase inhibitors such as anastrozole, letrozole, and exemestane work by lowering the amount of estrogen in the body. They starve the receptor of its fuel. Certain ESR1 mutations change the shape of the receptor so it switches on by itself, without estrogen bound to it. Lowering estrogen further then achieves nothing, because the receptor is no longer waiting for it.

That is why an ESR1 mutation usually signals resistance to aromatase inhibitors specifically, rather than to all hormone treatment.

The relevant mutations cluster in one region of the gene, the ligand binding domain. That is the pocket that normally holds estrogen.

The FDA-approved companion test defines this narrowly. Selection for elacestrant was based on the Guardant360 CDx assay and was limited to ESR1 missense mutations in the ligand binding domain, between codons 310 and 547. A missense mutation is one that swaps a single amino acid.

So "ESR1 mutation detected" on a report is not automatically the same as the mutation the drug approval refers to. It is fair to ask which specific change was found, and which codon.

Patient selection for elacestrant is based on finding ESR1 mutations in a plasma specimen, meaning blood, using an FDA-authorized test. This is a liquid biopsy that detects circulating tumor DNA.

There is a reason blood rather than tissue is used. ESR1 mutations arise over time and can differ between deposits of cancer in different parts of the body. An archived tumor block from the original operation would predate the mutation entirely. Blood samples what is circulating now.

Timing therefore matters. Testing at the point of progression on endocrine therapy is more informative than testing at diagnosis, and repeat testing later can turn a negative into a positive.

Elacestrant (Orserdu) is an oral selective estrogen receptor degrader. Instead of blocking the receptor, it causes the receptor protein to be broken down.

Its label covers postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, whose disease has progressed after at least one line of endocrine therapy. The label's once-daily strength is 345 mg by mouth, taken with food at roughly the same time each day, and continued until the cancer progresses or the side effects stop being tolerable. Treat that as background, not as instructions: the strength on your own prescription is the one to follow, because your oncologist may have set it lower.

Practical details from the label:

• Swallow the tablets whole. Do not chew, crush, or split them.
• Do not take tablets that are broken, cracked, or damaged.
• If a dose is missed by more than 6 hours, or if you vomit, skip it and take the next dose at the usual time the following day.
• If side effects bite, the prescriber can step the daily amount down, and there is a floor below which the label says to stop the drug for good rather than keep going. Those steps are theirs to make, not yours.

In the EMERALD trial, 228 patients with ESR1 mutations were randomly assigned to elacestrant or to standard care, meaning fulvestrant or an aromatase inhibitor. All had already received a CDK4/6 inhibitor.

Median progression-free survival was 3.8 months with elacestrant and 1.9 months with standard care. The hazard ratio was 0.55.

Overall survival did not differ. The hazard ratio was 0.90, and the result was not statistically significant.

Those are the real numbers. The gain is a delay in progression measured in weeks to a few months, in a group whose alternatives had already stopped working. Whether that trade is worth taking is a legitimate personal decision, and having the figures makes it an informed one.

Across 237 patients on elacestrant in EMERALD, the common side effects included musculoskeletal pain in 41 percent, nausea in 35 percent, vomiting in 19 percent, diarrhea in 13 percent, constipation in 12 percent, abdominal pain in 11 percent, and indigestion in 10 percent. Taking it with food is specifically intended to reduce nausea.

Serious adverse reactions occurred in 12 percent. Treatment was stopped permanently for side effects in 6 percent, interrupted in 15 percent, and reduced in 3 percent. Fatal adverse reactions occurred in 1.7 percent.

The label carries one warning to plan for. Elacestrant can cause high cholesterol and high triglycerides, so lipid levels are monitored.

• Which specific ESR1 mutation was found, and at which codon?
• Was this a blood test or tissue, and when was the sample taken?
• If tissue was negative, is a blood test at progression worth doing now?
• Given my prior treatments, does this result change the next drug?
• What is the realistic expected benefit for me, in months?
• When will my cholesterol and triglycerides be checked?

• Vomiting that stops you keeping the tablet down for more than 24 hours.
• Six or more loose stools a day above your normal.
• New severe bone or muscle pain, or pain in one spot that worsens over days.
• New shortness of breath, chest pain, or a swollen painful calf.
• Yellow eyes or skin, or dark urine.
• Fever of 100.4 F (38 C) or higher.

Breast Cancer, Hormone Therapy, What Does ER/PR Status Mean?, and Liquid Biopsy vs Tissue Biopsy.

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef
• https://www.cancer.gov/about-cancer/treatment/drugs/elacestrant-dihydrochloride